US Trial For Chronic Atrial Fibrillation
Ablation Frontiers is currently sponsoring the first ever US clinical trial for minimally-invasive (percutaneous) treatment of chronic atrial fibrillation. The US Food and Drug Administration (FDA) approved the study based on the review of an initial feasibility segment completed in August 2007. New patient enrollment is currently underway, having begun at the end of 2007.
The study, known as the Tailored Treatment of Permanent Atrial Fibrillation (TTOP AF), uses an approach that allows cardiologists to customize their treatment strategy and potentially shorten procedure times, improve patient outcomes, and reduce recurrence of the disease.
Patients will initially be randomized into two treatment groups; one group receiving ablation  therapy, and the other group – called the control arm – receiving commonly used drug treatments. For every two patients initially receiving an ablation, one will be randomly assigned to the control arm. The trial allows patients in the control arm to receive an ablation if they do not respond to drug therapy.
To see if you or someone you know is eligible to participate in the TTOP AF study, please call: 1.877.600.1QRS or Contact US. More information is available on the National Institutes of Health web page.
To see a list of US sites supporting this trial, click here.
 Contacts
Home
|
